Compile Data Set for Download or QSAR
Report error Found 826 Enz. Inhib. hit(s) with all data for entry = 2764
TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380077(US9926282, Example 72)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380076(US9926282, Example 71)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380078(US9926282, Example 73)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380072(US9926282, Example 68 | US9926282, Example 69 | N-...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380072(US9926282, Example 68 | US9926282, Example 69 | N-...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380075(US9926282, Example 70)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380083(US9926282, Example 79 | US9926282, Example 78)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380083(US9926282, Example 79 | US9926282, Example 78)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380083(US9926282, Example 79 | US9926282, Example 78)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380085(US9926282, Example 80)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380085(US9926282, Example 80)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380080(US9926282, Example 75)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380080(US9926282, Example 75)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380079(US9926282, Example 74)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM197990(US9221767, 76 | US9926282, Example 77)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM197990(US9221767, 76 | US9926282, Example 77)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380081(US9926282, Example 76)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380081(US9926282, Example 76)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380092(US9926282, Example 87)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380091(US9926282, Example 86)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380094(N-[4-(4-oxo-3,4- dihydrophthalazin-1- yl)phenyl]im...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380093(US9926282, Example 88)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380088(US9926282, Example 83)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380088(US9926282, Example 83)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380090(US9926282, Example 85)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380090(US9926282, Example 85)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380089(US9926282, Example 84)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380100(2-methyl-N-[4-(4-oxo- 3,4-dihydrophthalazin-1- yl)...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380100(2-methyl-N-[4-(4-oxo- 3,4-dihydrophthalazin-1- yl)...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380099(6-(dimethylamino)-N-[4- (4-oxo-3,4- dihydrophthala...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380099(6-(dimethylamino)-N-[4- (4-oxo-3,4- dihydrophthala...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380101(5-chloro-1-methyl-N-[4- (4-oxo-3,4- dihydrophthala...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380096(N-[4-(4-oxo-3,4- dihydrophthalazin-1- yl)phenyl]-2...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380095(1-methyl-N-[4-(4-oxo- 3,4-dihydrophthalazin-1- yl)...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380098(N-[4-(4-oxo-3,4- dihydrophthalazin-1- yl)phenyl]-2...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380098(N-[4-(4-oxo-3,4- dihydrophthalazin-1- yl)phenyl]-2...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380097(N-[4-(4-oxo-3,4- dihydrophthalazin-1- yl)phenyl]-4...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380108(N-[4-(4-oxo-3,4- dihydrophthalazin-1- yl)phenyl]py...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380108(N-[4-(4-oxo-3,4- dihydrophthalazin-1- yl)phenyl]py...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380107(N-[4-(4-oxo-3,4- dihydrophthalazin-1- yl)phenyl]py...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380107(N-[4-(4-oxo-3,4- dihydrophthalazin-1- yl)phenyl]py...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380110(5-(benzyloxy)-2-methyl- N-[4-(4-oxo-3,4- dihydroph...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380109(N-[4-(4-oxo-3,4- dihydrophthalazin-1- yl)phenyl]im...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380109(N-[4-(4-oxo-3,4- dihydrophthalazin-1- yl)phenyl]im...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380104(1-benzyl-N-[4-(4-oxo- 3,4-dihydrophthalazin-1- yl)...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380104(1-benzyl-N-[4-(4-oxo- 3,4-dihydrophthalazin-1- yl)...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380103(1-methyl-N-[4-(4-oxo- 3,4-dihydrophthalazin-1- yl)...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380103(1-methyl-N-[4-(4-oxo- 3,4-dihydrophthalazin-1- yl)...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 2(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380106(5-methyl-N-[4-(4-oxo- 3,4-dihydrophthalazin-1- yl)...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

TargetRho-associated protein kinase 1(Human)
Bristol-Myers Squibb

US Patent
LigandPNGBDBM380106(5-methyl-N-[4-(4-oxo- 3,4-dihydrophthalazin-1- yl)...)
Affinity DataIC50: 100nMAssay Description:The effectiveness of compounds of the present invention as ROCK inhibitors can be determined in a 30 μL assay containing 20 mM HEPES, pH 7.5, 20...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/10/2020
Entry Details
US Patent

Displayed 1 to 50 (of 826 total ) | Next | Last >>
Jump to: